Kangyuan pharmaceutical actively distributes research and development of biological drugs

Kangyuan Pharmaceutical (600557 SH), a leading Chinese patent medicine innovation enterprise, plans to further expand its product line to biopharmaceuticals At present, the group is actively distributing biopharmaceutical field through independent research and development and extended M & A, the company said At the level of independent research and development, the group set up a biopharmaceutical company three years ago to carry out relevant drug research and development It is expected that two varieties will apply for new drug certificates this year In terms of extension M & A, the group company will acquire a biopharmaceutical enterprise in the near future At present, the biopharmaceutical company has a thrombolytic drug under research It is worth mentioning that executives of Kangyuan Pharmaceutical Co., Ltd made it clear in a telephone conference recently that biopharmaceuticals are the development strategy of the company and will be incorporated into the listed companies to support the development of new business of Kangyuan in the future through appropriate methods Kangyuan Pharmaceutical Co., Ltd is mainly engaged in the research, development, production and sales of Chinese patent medicines The core product of the company, Reduning injection, contributes nearly 50% of its business income Qilu Securities research report pointed out that, based on the analysis of the company's own resources and R & D advantages, the group has actively carried out exploration in the field of biopharmaceutics It is expected that in the next three years, a biopharmaceutical platform with certain core competitiveness will be formed and incorporated into the listed companies.